The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of S-1 plus oxaliplatin (OX) at dose of 130 mg/m2 (SOX130) in Japanese patients (pts) with advanced gastric cancer (AGC).
 
Yosuke Kito
No Relationships to Disclose
 
Nozomu Machida
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Satoshi Hamauchi
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Akiko Todaka
No Relationships to Disclose
 
Tomoya Yokota
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Akira Fukutomi
Honoraria - Taiho Pharmaceutical
 
Yusuke Onozawa
No Relationships to Disclose
 
Kunihiro Tsuji
No Relationships to Disclose
 
Hisashi Doyama
No Relationships to Disclose
 
Yutaka Haraguchi
No Relationships to Disclose
 
Koji Nakashima
No Relationships to Disclose
 
Kenji Kunieda
No Relationships to Disclose
 
Keisei Taku
No Relationships to Disclose
 
Keita Mori
No Relationships to Disclose
 
Hirofumi Yasui
No Relationships to Disclose